TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31127468

Group type: EXPERIMENTAL
Intervention: Integrated consent model (ICM) with oral consent
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Standard of care interventions (including surgical, adjuvant chemotherapy, supportive care, radiology, vascular devices, palliative care, molecular diagnostics)
Number of subjects: 2000
Study: 28943492

Group type: EXPERIMENTAL
Intervention: PPH plus single‐purse suture (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: PPH plus multipoint umbrella suture (Group B)
Number of subjects: 90
Study: 26033220

Group type: EXPERIMENTAL
Intervention: neoadjuvant axitinib therapy
Number of subjects: 22
Study: 23663409

Group type: EXPERIMENTAL
Intervention: Spoken presentation of negative training
Number of subjects: 94

Group type: COMPARATOR
Intervention: Written presentation of negative training
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Spoken presentation of benign training
Number of subjects: 94

Group type: COMPARATOR
Intervention: Written presentation of benign training
Number of subjects: 94
Study: 22264208

Group type: EXPERIMENTAL
Intervention: 1% Alendronate (ALN) gel
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 70
Study: 19129280

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Formoterol alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17472820

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 to 10 mg + Valsartan 160 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Lisinopril 10 to 20 mg + HCTZ 12.5 mg
Number of subjects: 130
Study: 15262126

Group type: EXPERIMENTAL
Intervention: CMC regimen (carboplatin 1500 mg/m², mitoxantrone 75 mg/m², cyclophosphamide 120 mg/kg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: CTC regimen (cisplatin 165 mg/m², thiotepa 600 mg/m², cyclophosphamide 5625 mg/m²)
Number of subjects: 67
Study: 11827498

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulation
Number of subjects: 0
Study: 10682563

Group type: EXPERIMENTAL
Intervention: Metoprolol plus routine therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Routine therapy only
Number of subjects: 43
Study: 8565696

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone caproate
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of AG and hydroxyprogesterone caproate
Number of subjects: 39
Study: 2474097

Group type: EXPERIMENTAL
Intervention: Captopril or Enalapril (ACE inhibitors) for 2-6 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril or Enalapril combined with Mepitiostane (antiestrogenic steroid)
Number of subjects: 12
Study: 105098

Group type: EXPERIMENTAL
Intervention: Levamisole therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31274602

Group type: EXPERIMENTAL
Intervention: Acetaminophen 15 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30845265

Group type: EXPERIMENTAL
Intervention: LMS method of standardisation for language measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online calculator for estimating standardised scores
Number of subjects: 0
Study: 28555508

Group type: COMPARATOR
Intervention: Conventional 120‐kVp scan with a CM volume of 70 ml and an injection rate of 5 ml s‐1 (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ssDECT scan with CM volume of 0.6 ml/kg and 40% ASIR (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ssDECT scan with CM volume of 0.4 ml/kg and 50% ASIR (Group C)
Number of subjects: 120
Study: 26692559

Group type: EXPERIMENTAL
Intervention: Multimodal periarticular anaesthetic infiltration
Number of subjects: 264

Group type: COMPARATOR
Intervention: Femoral nerve anaesthetic blockade
Number of subjects: 264
Study: 23764765

Group type: EXPERIMENTAL
Intervention: Mini-open approach (MO-TLIF)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Classic open approach (CL-TLIF)
Number of subjects: 41
Study: 21693058

Group type: EXPERIMENTAL
Intervention: Multimedia teaching method for ankle/foot examination techniques
Number of subjects: 45

Group type: COMPARATOR
Intervention: Live demonstration for knee examination techniques
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multimedia teaching method for knee examination techniques
Number of subjects: 45

Group type: COMPARATOR
Intervention: Live demonstration for ankle/foot examination techniques
Number of subjects: 45
Study: 18584319

Group type: EXPERIMENTAL
Intervention: Mutual support group
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard psychiatric care
Number of subjects: 76
Study: 16584285

Group type: COMPARATOR
Intervention: Tagamet 400mg tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7.5% methacrylate copolymer cimetidine tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15% methacrylate copolymer cimetidine tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 26% methacrylate copolymer cimetidine tablet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tagamet (300 mg/2 mL) intravenous injection
Number of subjects: 12
Study: 12706917

Group type: EXPERIMENTAL
Intervention: Eptifibatide 180 microg/kg bolus, 2 microg/kg/min infusion, and 180 microg/kg bolus 10 min later (180/2/180) plus half-dose TNK (0.27 mg/kg)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Standard-dose TNK monotherapy (0.53 mg/kg)
Number of subjects: 438
Study: 11097963

Group type: EXPERIMENTAL
Intervention: Imipramine (180 mg/day)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Buspirone (38 mg/day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 8866527

Group type: EXPERIMENTAL
Intervention: Shaping instruction for behavioral tests
Number of subjects: 74
Study: 1473889

Group type: EXPERIMENTAL
Intervention: Ender nails
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 92
Study: 6385868

Group type: EXPERIMENTAL
Intervention: Cimetidine (20 mg/kg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Antacids (Maalox, 700 mmol (mEq)/1 X 73 m2/day)
Number of subjects: 33
Study: 31371341

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 416

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 416

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: PD-L1 positive TC
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Combined analysis of both trials
Number of subjects: 416
Study: 27893563

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) - 12 weeks, 8 exercises, 3 sets of 8 to 12 repetitions at 75% 1-RM, 3 times per week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control - Usual care and maintenance of daily activities
Number of subjects: 30
Study: 25963053

Group type: EXPERIMENTAL
Intervention: Post-radiotherapy biopsy
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Positive post-treatment biopsy
Number of subjects: 303
Study: 23303466

Group type: EXPERIMENTAL
Intervention: WDYD intervention (web-based brief alcohol intervention)
Number of subjects: 913

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 913
Study: 21622815

Group type: EXPERIMENTAL
Intervention: Centrally placed polyethylene screw and sheath implant (INTRAFIX)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Metal interference screw and staples (RCI)
Number of subjects: 113
Study: 18452437

Group type: EXPERIMENTAL
Intervention: Curcuminoids hydrogel patch with squid chitosan (1:1 ratio of curcuminoids microemulsion to polymer solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curcuminoids hydrogel patch with squid chitosan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curcuminoids hydrogel patch
Number of subjects: 0
Study: 16490726

Group type: EXPERIMENTAL
Intervention: Combination of propacetamol 2 g and ketorolac 30 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12824718

Group type: EXPERIMENTAL
Intervention: Angina-free patients undergoing CABG
Number of subjects: 590

Group type: COMPARATOR
Intervention: Patients with angina undergoing CABG
Number of subjects: 590
Study: 10617941

Group type: EXPERIMENTAL
Intervention: SFA-rich meal
Number of subjects: 32

Group type: COMPARATOR
Intervention: Combined groups (SFA and MUFA-rich meals)
Number of subjects: 32
Study: 9188930

Group type: EXPERIMENTAL
Intervention: 0.05% mequitazine eye-drops, four times daily for 5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20
Study: 8166477

Group type: EXPERIMENTAL
Intervention: Surgery followed by aggressive randomized chemotherapy and PCI
Number of subjects: 186

Group type: COMPARATOR
Intervention: Preoperative (neoadjuvant) chemotherapy followed by surgery
Number of subjects: 186
Study: 31344268

Group type: EXPERIMENTAL
Intervention: Maternal pre-pregnancy BMI
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Child lean body mass
Number of subjects: 201

Group type: COMPARATOR
Intervention: Gestational diabetes, pre-pregnancy BMI, child body fat percentage
Number of subjects: 201
Study: 29064536

Group type: EXPERIMENTAL
Intervention: Flow-mediated dilatation (FMD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No-therapy
Number of subjects: 90
Study: 27236388

Group type: EXPERIMENTAL
Intervention: Teaching attachment behaviors to pregnant women (six educational sessions lasting 60-90 minutes)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Teaching attachment behaviors to pregnant women
Number of subjects: 190
Study: 26214039

Group type: EXPERIMENTAL
Intervention: Dengue vaccine
Number of subjects: 35165

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35165
Study: 22917554

Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil (6 μg/breath, 3 to 9 breaths, 4 times/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Number of subjects: 29
Study: 20477784

Group type: EXPERIMENTAL
Intervention: Propofol target effect-site concentration of 6.0 microgxml(‐1)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Propofol target effect-site concentrations of 0 and 3.0 microgxml(‐1)
Number of subjects: 400
Study: 17923329

Group type: EXPERIMENTAL
Intervention: private verbal emotional disclosure
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: clinician-assisted verbal emotional disclosure
Number of subjects: 98

Group type: COMPARATOR
Intervention: arthritis information control
Number of subjects: 98

Group type: COMPARATOR
Intervention: no-treatment, standard care only control
Number of subjects: 98
Study: 15906109

Group type: EXPERIMENTAL
Intervention: Native sodium hyaluronate (group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cross‐linked hylan G‐F 20 (group II)
Number of subjects: 40
Study: 11817922

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention over 10 weeks
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 10516734

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 9041079

Group type: EXPERIMENTAL
Intervention: Topical interferon alpha 2b (IFN‐alpha) 5 x 10(6) IU/ml, four times daily for 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Topical interferon alpha 2b (IFN‐alpha) for patients with correction > 5.00 D
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Topical interferon alpha 2b (IFN‐alpha)
Number of subjects: 31
Study: 1552999

Group type: EXPERIMENTAL
Intervention: Intravenous 1-alpha-hydroxyvitamin D3 (1 alpha‐OH‐D3) after each dialysis at increasing doses up to 4 micrograms, with Mg(OH)2 as sole phosphate binder.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intravenous 1-alpha-hydroxyvitamin D3 (1 alpha‐OH‐D3) with Mg(OH)2 as sole phosphate binder.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3) as phosphate binder.
Number of subjects: 47
Study: 3991397

Group type: EXPERIMENTAL
Intervention: Diumide K (frusemide 40 mg, potassium 8 mmol)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Burinex K (bumetanide 0.5 mg, potassium 7.7 mmol)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Frusemide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bumetanide
Number of subjects: 28
Study: 31858429

Group type: EXPERIMENTAL
Intervention: Lenalidomide + rituximab (R2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rituximab + placebo (R-placebo)
Number of subjects: 36
Study: 29626369

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 20
Study: 27407058

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Number of subjects: 87

Group type: COMPARATOR
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 87
Study: 25347304

Group type: EXPERIMENTAL
Intervention: Educational clips featuring Hispanic traditions and words
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Educational clips featuring Chinese traditions and words
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Educational clips featuring characters (Hispanic, Chinese American, Anglo)
Number of subjects: 259
Study: 22268900

Group type: EXPERIMENTAL
Intervention: Semantic therapy (two 15-min sessions per week for 8 weeks) targeting words from semantic categories (animals, food, clothes)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Waiting control group (no therapy in Phase 1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined effect of therapy over the two groups
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pre-therapy TAWF scores
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Post-therapy TAWF scores
Number of subjects: 15
Study: 20625396

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Flecainide in Arg389Arg genotype
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Flecainide in Arg389Gly genotype
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Flecainide in Gly389Gly genotype
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Flecainide in Arg389Gly-Ser49Gly genotype
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Heart rate during atrial fibrillation in Arg389Arg genotype
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Heart rate during atrial fibrillation in Arg389Gly genotype
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Heart rate during atrial fibrillation in Gly389Gly genotype
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Arg389Gly-Ser49Gly genotype prevalence
Number of subjects: 145
Study: 18805105

Group type: EXPERIMENTAL
Intervention: Framingham risk score (FRS) low risk group (FRS <10%)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Framingham risk score (FRS) intermediate risk group (FRS 10% to 20%)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Framingham risk score (FRS) high risk group (FRS >20%)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Subjects with atherosclerosis in the low risk group
Number of subjects: 498
Study: 15682364

Group type: EXPERIMENTAL
Intervention: Pharmacologic stress myocardial perfusion imaging (adenosine or dipyridamole)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pharmacologic stress myocardial perfusion imaging
Number of subjects: 93

Group type: COMPARATOR
Intervention: Clinical score
Number of subjects: 93
Study: 11919132

Group type: EXPERIMENTAL
Intervention: 30 microg pramlintide q.i.d.
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 30 or 60 microg pramlintide q.i.d. (open-label extension)
Number of subjects: 480
Study: 10450297

Group type: EXPERIMENTAL
Intervention: DASH dietary pattern
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459
Study: 7562730

Group type: EXPERIMENTAL
Intervention: 0.2 percent neutral NaF solution rinsed once a week
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: 2.2 mg NaF tablet chewed, rinsed, and swallowed daily
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Both procedures (mouthrinse and tablet)
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Control group (no fluoride treatment)
Number of subjects: 1640
Study: 1287559

Group type: COMPARATOR
Intervention: CORN oil infant formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: SOY oil infant formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 0
Study: 4073086

Group type: EXPERIMENTAL
Intervention: ticarcillin plus clavulanic acid
Number of subjects: 90

Group type: COMPARATOR
Intervention: cefoxitin
Number of subjects: 90

Group type: COMPARATOR
Intervention: tobramycin plus piperacillin
Number of subjects: 90
Study: 31341122

Group type: EXPERIMENTAL
Intervention: Dental treatment (DT) perceived as a cause of OMLs
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Denture placement
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Implant treatment
Number of subjects: 280

Group type: COMPARATOR
Intervention: Chief complaint site (CC)
Number of subjects: 280
Study: 30570869

Group type: EXPERIMENTAL
Intervention: NBASS‐APS pain management model
Number of subjects: 228

Group type: COMPARATOR
Intervention: C‐APS (customary APS)
Number of subjects: 228
Study: 27010770

Group type: EXPERIMENTAL
Intervention: 1,064-nm LPNY laser (Group A: 0.3 ms pulse duration, 5 mm spot size, 16 J/cm2 fluence, 10 Hz frequency)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1,064-nm LPNY laser (Group B: 0.6 ms pulse duration, 2 mm spot size, 225 J/cm2 fluence, 5 Hz frequency)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1,064-nm LPNY laser (both groups)
Number of subjects: 13
Study: 24033222

Group type: EXPERIMENTAL
Intervention: Causally rich information
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Causally weak information
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Tangible reward
Number of subjects: 56

Group type: COMPARATOR
Intervention: No reward (baseline condition)
Number of subjects: 56
Study: 22374555

Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Vitamin A plus zinc (AZ group)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Vitamin A combined with multiple micronutrients (AMM group)
Number of subjects: 290
Study: 20374670

Group type: EXPERIMENTAL
Intervention: Behavioral activation therapy, provided weekly for 4 months followed by monthly sessions for 4 months.
Number of subjects: 1
Study: 17493183

Group type: EXPERIMENTAL
Intervention: Cefepime 1 g intramuscularly every 24 hours
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g intramuscularly every 24 hours
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cefepime and Ceftriaxone
Number of subjects: 69
Study: 16198825

Group type: EXPERIMENTAL
Intervention: High b‐value diffusion imaging (q‐space imaging)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 15
Study: 11995875

Group type: EXPERIMENTAL
Intervention: Non-invasive surgical zipper (Medizip)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intracutaneous sutures
Number of subjects: 120
Study: 10365924

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7572690

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study: 2248837

Group type: EXPERIMENTAL
Intervention: Diclofenac 1 mg kg‐1 i.m.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram kg‐1 i.v.
Number of subjects: 60

Group type: COMPARATOR
Intervention: No analgesic (placebo)
Number of subjects: 60
Study: 471153

Group type: EXPERIMENTAL
Intervention: Ticrynafen (TCNF)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 25
Study: 30680830

Group type: EXPERIMENTAL
Intervention: PVI + RDN
Number of subjects: 387

Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: RDN
Number of subjects: 387
Study: 28236299

Group type: EXPERIMENTAL
Intervention: Platelet Efficacy Score (PEscore)
Number of subjects: 1592
Study: 25873334

Group type: EXPERIMENTAL
Intervention: Tai Chi group (n = 71)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Routine exercise group (n = 71)
Number of subjects: 142
Study: 24193288

Group type: EXPERIMENTAL
Intervention: Absorbable fibrin sealant patch (AFSP)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Standard surgical treatment (ST)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Absorbable fibrin sealant patch (AFSP) and Standard surgical treatment (ST)
Number of subjects: 346
Study: 21391017

Group type: EXPERIMENTAL
Intervention: Incredible Years parent and child training programs
Number of subjects: 99
Study: 19214861

Group type: EXPERIMENTAL
Intervention: 1064 nm Nd:YAG laser treatment (fluence 30 J/cm, 18 mm spot size, dynamic cooling device pulse duration of 30 ms)
Number of subjects: 12
Study: 17202429

Group type: EXPERIMENTAL
Intervention: Reminder
Number of subjects: 0

Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 0
Study: 14765876

Group type: EXPERIMENTAL
Intervention: Paediatric cell saver used to collect autologous blood
Number of subjects: 22

Group type: COMPARATOR
Intervention: Banked homologous blood transfusion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Paediatric cell saver
Number of subjects: 22